Reference is made to the stock exchange announcement made on 27 September 2024 with key information regarding the consolidation (reverse split) of the Company’s shares and the warrants issued by the Company pursuant to a resolution made by the extraordinary general meeting held on 16 May 2024 (the “Warrants”). The following information is provided in connection with the ex. date for the consolidation (reverse split) of shares and Warrants:
Issuer name: Lifecare ASA
Ex. date: 1 October 2024
Type of corporate action: Consolidation (reverse split) of shares and Warrants
This information is published in accordance with the requirements of the Continuing Obligations.
About Lifecare:
Lifecare is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.